Previous Article | Next Article ![]()
Applied and Environmental Microbiology, March 2008, p. 1932-1935, Vol. 74, No. 6
0099-2240/08/$08.00+0 doi:10.1128/AEM.02334-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
-Terpineol
Discipline of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia,1 Division of Microbiology and Infectious Diseases, PathWest Laboratory Medicine WA, Queen Elizabeth II Medical Centre, Nedlands, Western Australia 6009, Australia2
Received 29 September 2007/ Accepted 3 January 2008
|
|
|---|
-terpineol. These data show that a multidrug efflux system of P. aeruginosa can extrude monoterpenes and related alcohols. |
|
|---|
Derived from the Australian native plant Melaleuca alternifolia (Myrtaceae), tea tree oil (TTO) is an established broad-spectrum topical antimicrobial agent (2). Composed of terpene hydrocarbons, mainly monoterpenes, sesquiterpenes and their related alcohols, the composition of commercial TTO is regulated by an international standard (15). The oil has antibacterial, antiviral, and antifungal properties verified both in vitro and in a number of clinical trials (2). P. aeruginosa is less susceptible than most bacterial species to TTO, with MICs ranging from 1 to 8%, compared to <0.5% for other gram-negative bacteria (1, 2, 27). The activity of TTO and terpinen-4-ol, its main antimicrobial component, against P. aeruginosa is enhanced by the protonophore carbonyl cyanide m-chlorophenylhydrazone and the outer membrane chelator EDTA (9, 22). To elucidate the role of efflux pumps in tolerance to TTO, the susceptibility of a series of well-characterized efflux pump mutants of P. aeruginosa to TTO and five of its monoterpene components, terpinen-4-ol, 1,8-cineole,
-terpineol,
-terpinene, and
-cymene, was examined.
The bacterial strains used in the present study are listed in Table 1. TTO (batch W/E504) was kindly provided by Australian Plantations Pty., Ltd., Wyrallah, New South Wales, Australia. The levels of the components determined by gas chromatography analysis and the range specified by the international standard (15) (shown in parentheses) were as follows: 40.3% (>30%) terpinen-4-ol, 19.7% (10 to 28%)
-terpinene, 8.6% (5 to 13%)
-terpinene, 3.2% (0 to 15%) 1,8-cineole, 3.2% (1.5 to 5%) terpinolene, 3.1% (1.5 to 8%)
-terpineol, 2.4% (1 to 6%)
-pinene, 2.4% (0.2 to 12%)
- cymene, 1.6% (trace [tr] to 7%) aromadendrene, 1.2% (tr to 8%)
-cadinene, 1.0% (0.5 to 4%) limonene, 0.5% (tr to 3%) globulol, 0.4% (tr to 1.5%) viridiflorol, and 0.1% (tr to 3.5%) sabinene. Terpinen-4-ol (100% pure) was provided by SNP Natural Products (Sydney, New South Wales, Australia). 1,8-Cineole (99% pure),
-terpineol (95% pure), and phe-arg-β-naphthylamide dihydrochloride (PAβND) were purchased from Sigma Chemical Company (St. Louis, MO).
-Terpinene (97% pure) and
-cymene (99% pure) were purchased from Aldrich Chemical Company (Milwaukee, WI). Terpinen-4-ol and
-terpineol were selected on the basis of their marked antimicrobial activity (2).
-Terpinene and
-cymene were selected since they are regarded as less antimicrobially active components, and 1,8-cineole was selected because it has modest activity and may be important for permeabilizing the outer membrane (3).
|
View this table: [in a new window] |
TABLE 1. Characteristics and TTO and component susceptibilities for efflux mutants and wild-type strains
|
-terpineol,
-terpinene, and
-cymene were determined for the various efflux mutants and their wild-type strains by using the broth microdilution method described by the Clinical and Laboratory Standards Institute (7) with the following modification: all tests were performed in Mueller-Hinton broth supplemented with 0.002% Tween 80 (MHB-T). The compounds were tested over the range of 0.125 to 8% (vol/vol), and the MIC was the lowest concentration of TTO or component in which no growth was observed. Tests were performed at least three times, and a modal value was selected. In other MIC assays, PAβND, a known inhibitor of efflux in P. aeruginosa (8, 16), was added at 20 µg/ml. Differences in MICs determined for the various efflux mutants and their wild-type strains of
4-fold were considered significant. The susceptibility of efflux pump mutants to TTO and terpinen-4-ol was also examined by using time-kill assays. A total of 10 ml of MHB was inoculated with one colony from a 24-h blood agar culture of P. aeruginosa, followed by incubation for 16 to 20 h at 35°C with shaking. This culture was diluted 1:100 with MHB-T to yield a 50-ml volume of suspension with approximately 107 CFU/ml. A 9.1-ml volume of cell suspension was dispensed into a 50-ml flask for each treatment or control. The treatments were 0.25 or 4% TTO or 0.125 or 1% terpinen-4-ol. At 5 min prior to time zero, 100 µl was removed, serially diluted in phosphate-buffered saline (PBS), and spread plated in duplicate onto predried nutrient agar plates. At time zero, a 1-ml aliquot of TTO, terpinen-4-ol, or PBS was added to the flask; the contents were then mixed for 20 s, and a 100-µl aliquot was removed for serial dilution at 0.5 min. The first 1:10 dilution of the aliquot was made in neutralizer (25) to arrest the effect of the oil or terpinen-4-ol. This first dilution was vortex mixed and left at room temperature for a minimum of 5 min to allow neutralization to occur. After this, the remaining dilutions were made in PBS. Flasks were incubated at 35°C with shaking for the 120-min duration of the assay. Samples were taken at 5, 10, 15, 20, 30, 60, and/or 120 min and were neutralized, diluted, and plated as at 0.5 min. Nutrient agar plates were incubated at 37°C overnight, and the viable count was determined.
Complementation of mutants deficient in MexAB-OprM was achieved by transforming with pRSP17 (pRK415::mexAB-oprM). The plasmids pRK415 and pRSP17 were extracted from E. coli strains K340 (17) and K1154 (31) (provided by Keith Poole), respectively. Cell suspensions of recipient strains of P. aeruginosa were prepared using a method based on that of Choi et al. (4). Cells were electroporated with plasmid in a Bio-Rad Gene Pulser II at 25 µF, 200
, and 2.5 kV/cm for approximately 5 ms. Luria broth was added, and the cells were incubated in a sterile Bijou bottle at 37°C for 2 h with shaking. The mixture was plated onto a Luria agar plate containing 10 µg of tetracycline/ml, followed by incubation overnight at 37°C. A plasmid miniprep confirmed the presence of the respective plasmids in several transformants, and the MICs of TTO and terpinen-4-ol for the transformants and wild-type strains were determined by broth microdilution as described above, with 10 µg of tetracycline/ml added for transformants.
PAO200, K1119, and K1121, all MexAB-OprM–, and the MexB– and OprM– strains K1523 and K1110, respectively, showed an increase in susceptibility to TTO, terpinen-4-ol, 1,8-cineole, and
-terpineol compared to wild-type strains (Table 1). This increase ranged from 4 to 8 times for TTO, 4 to >16 times for terpinen-4-ol, >2 to >4 times for 1,8-cineole, and 8 to >16 times for
-terpineol. Hyperexpression of MexAB-OprM in K1112 made no significant change in susceptibility to TTO, and any changes in component susceptibility were beyond the detection limits of the assay due to component immiscibility at >8% (vol/vol). In time-kill assays with MexAB-OprM– strain K1121, one-quarter of the TTO MIC for that isolate reduced viability by 90% compared to slight growth in the ML5087 wild type (Fig. 1A). Treatment with 4% TTO (the MIC for the ML5087 wild type) caused a drop in viability below the limit of detection of the assay (3 x 103 CFU/ml) within 20 min in K1121, while only a 90% decrease in viability was seen in ML5087 after 120 min (Fig. 1A). Treatment with sub-MIC concentrations of terpinen-4-ol killed >90% of the MexAB-OprM– strain K1121 after 120 min but allowed growth in ML5087 (Fig. 1B).
![]() View larger version (9K): [in a new window] |
FIG. 1. Influence of the MexAB-OprM efflux system on the susceptibility of P. aeruginosa to TTO and terpinen-4-ol. (A) P. aeruginosa ML5087 treated with 0.25% ( ) or 4% ( ) TTO. K1121 (MexAB-OprM–) treated with 0.25% ( ) or 4% ( ) TTO. (B) P. aeruginosa ML5087 treated with 0.125% ( ) or 1% ( ) terpinen-4-ol. K1121 treated with 0.125% ( ) terpinen-4-ol. The MICs of TTO and terpinen-4-ol were 4 and >8%, respectively, for ML5087 and 1 and 0.5%, respectively, for K1121. A broth-only growth control for each isolate was included. ML5087 () is shown as representative of both strains. The error bars represent the standard deviations of at least three duplicate assays.
|
The addition of the efflux inhibitor PAβND to broth microdilution assays decreased the TTO and terpinen-4-ol MICs for PAO1 to levels similar to those in MexAB-OprM– (PAO200 and K1119) and MexB– (K1523) strains (Table 2). Interestingly, there were further increases in the susceptibility of these three strains to terpinen-4-ol when PAβND was present, indicating that the MexAB-OprM pump may not be the only efflux system involved in tolerance to this component.
|
View this table: [in a new window] |
TABLE 2. Effect of PAβND on susceptibility to TTO and terpinen-4-ol in P. aeruginosa PAO1 and several efflux mutants
|
-terpineol MIC dropped from 1 to <0.125%. The TTO and terpinen-4-ol MICs were not altered. Similarly, two- to fourfold reductions in MICs of 1,8-cineole and
-terpineol were seen in K1115 (MexAB-OprM– and MexCD-OprJ–) compared to K1121 (MexAB-OprM–). Again, the TTO and terpinen-4-ol MICs remained the same. It may be that the MexCD-OprJ pump effluxes 1,8-cineole and
-terpineol more efficiently than TTO or terpinen-4-ol since tolerance to the latter agents did not change. However, this is difficult to explain on the basis of physicochemical properties since
-terpineol and terpinen-4-ol have very similar aqueous solubilities and octanol-water partition coefficients (2). That aside, previous studies have shown an additive effect on drug resistance from the simultaneous expression of resistance nodulation division efflux pumps (18). It seems likely that interplay between the MexAB-OprM and MexCD-OprJ pumps may contribute to tolerance to some components of TTO, including 1,8-cineole and
-terpineol. The MexXY pump usually requires the OprM component to export substrates, and so the loss of the MexAB-OprM pump may also cause a loss of function for MexXY (24). There was no change in the susceptibility of strain K1525 (lacking the MexXY components) compared to the wild-type strain (Table 1). K1523, which is deficient in MexB, and the two MexAB-OprM– strains PAO200 and K1119 had almost identical susceptibilities, indicating that this change in susceptibility was probably related solely to the loss of the MexAB-OprM pump and not to a loss of function of MexXY due to loss of the OprM component.
-Terpinene and
-cymene did not appear to be substrates of any of the pumps examined, although their low antimicrobial activities may have meant that changes to their MICs went undetected above the upper limit of the susceptibility test. Alternatively, we may not have examined the pumps for which they are substrates. Given that
-terpinene has demonstrated activity against P. aeruginosa under certain circumstances (22, 23), the latter seems more likely.
Susceptibility to TTO and the components terpinen-4-ol, 1,8-cineole and
-terpineol was increased in mutants missing the MexAB-OprM efflux pump or a component of the pump. Complementation studies showed that addition of the mexAB-oprM operon to deletion mutants restored the TTO and terpinen-4-ol susceptibility to that of the wild type, confirming the role of MexAB-OprM in tolerance to TTO and terpinen-4-ol. Interplay between the MexAB-OprM and MexCD-OprJ pumps may contribute toward tolerance of some components of TTO, including 1,8-cineole and
-terpineol. The possibility remains that other membrane pump systems not constitutively expressed, or not examined here, may contribute to the efflux of terpenes from P. aeruginosa. Nevertheless, this work further extends the already broad range of known substrates for MexAB-OprM to cyclic monoterpenes.
C.J.P. is supported by a Rural Industries Research and Development Corporation Ph.D. scholarship (UWA-82A).
Published ahead of print on 11 January 2008. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»